PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - Why Raise Capital?
The Power of Genuine Networking for Entrepreneurs With OneSixOne Ventures with Pablo Casilimas and Justis Mendez
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 202: Life Sciences Startups and Industry Developments with Gil Price, Life Sciences Leader
PODCAST: Williams Mullen's Raising Capital 101: A Securities Podcast - The Aspects of Raising Capital from Start-Ups to More Established Companies
Embracing Change & Community: The Keys To Startup Success With Chris Heivly
Welcome to “Lowenstein Africa Presents: Venture Voices”
Legal Challenges Part 1 – Setting Up Your Startup for Success
A Conversation with Janade du Plessis of Launch Africa Ventures: Balancing Sustainable Development with ROI
The Force is Strong with this One – Success and Paying it Forward with Co-Founder of ChannelAdvisor and Spiffy Scot Wingo
Hunting Outsized Returns with Jason Caplain of Bull City Venture Partners
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 182: Life Sciences Startups and Leadership with Scott Pancoast of Zylo Therapeutics
Through the Lens: From serial entrepreneur to neutral who gets deals done - Focus on Daniel Garrie
JONES DAY TALKS®: Corporate Venture Capital: Market Overview, Trends in Deal Terms, and Special Considerations
Business Better Podcast Episode: Investing in Consumer Brands – A Conversation with SBJ Capital
The Startup That's Rethinking Home Care: What Sets CareYaya Apart?
Inside the UK Legal Startup Scene, with Henry Humphreys
The Advantages of BVI Funds and How to Set One Up
Disrupting Systemic Economic Injustice in the Startup Ecosystem, with Resilient Ventures' Tom Droege and Keith Daniel
Oil & Gas M&A Deal Activity & Outlook--Part 1
Importance of Monetizing Intellectual Property Assets of a Portfolio Company
Many biopharmaceutical companies are facing challenges raising cash through traditional equity markets. While venture investment activity saw a slight increase in the first half of 2024 as compared to the equivalent period in...more
Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more
Heather and Matthew welcome Dr. Gil Price, who has had an impressive career in the life sciences industry as a recently retired executive and currently serves as a board member for numerous companies. As an experienced leader...more
For a succinct analysis of 1H 2024 venture investment and exit activity in life sciences and health care, take a look at HSBC’s Venture Healthcare Report, Shake it off: HSBC Innovation Banking Analysis, 1H 2024. Lead author...more
You’ve conceived the next great innovation, but actually pushing it out into the world is a whole other endeavor—and it's not cheap. For New York Tech Week, Fenwick corporate partner Al Cooper sat down with some of...more
This latest edition features articles on biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, life sciences venture financings for clients in 2023, and updated USPTO...more
As we countdown to NY Tech Week in just 15 days, here are 15 facts about the city's dynamic tech ecosystem....more
Wilson Sonsini’s 31st Annual Medical Device & Digital Health Conference will address topics of critical importance to medical device and digital health companies, including early and late-stage venture financing, partnering...more
It was another record-breaking year for the annual Bloom Burton & Co. Healthcare Investor Conference (BBHIC) in Toronto. The event brought together premier healthcare companies and investors from Canada and around the world....more
Our survey analyzed the terms of 171 venture financings closed in the fourth quarter of 2023 by companies headquartered in Silicon Valley. Fourth-quarter Bay Area venture capital financings remained largely flat from the...more
Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a...more
The year 2023 will be remembered as a challenging one for private equity (PE), with complexities to navigate on many fronts. Traditional debt financing was expensive and scarce, expectations on valuations were tricky to...more
Recorded at SCbio’s 2024 annual conference, Heather and Matthew are joined by Scott Pancoast, the Founder and CEO of Zylo Therapeutics, who also sits on the board of SCbio. Scott has an impressive track record of investing in...more
Key Findings - - U.S. investors show strong and sustained interest - Canadian government-backed funds lead domestic investment - Non-dilutive funding emerges as a dominant force - Majority of investments are in...more
As part of the Healey–Driscoll administration’s continued efforts to ensure Massachusetts remains a state where people want to live, work, and raise families — and businesses want to start and operate companies — the...more
In the second week of January, Goodwin and KPMG convened innovators, practitioners, regulators, and others for our annual symposium on the future of life sciences and healthcare. This marked the fifth year that Goodwin...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2023 include: • Life sciences VC deal value in Q4 2023 totaled $6.6 billion, representing a 25.0% decrease from the prior...more
The Fenwick life sciences team recently returned from the 2024 JP Morgan Healthcare conference. As we reflect back on the week, there were several key themes and trends that we expect will continue to resonate and evolve over...more
Digital health is showing signs of life despite financial markets that seem determined to bring some of 2023’s volatility into the new year. Stocks are up and down, and bond yields are climbing. Inflation is proving stubborn,...more
With the numbers tallied for the year behind us, we can confirm that funding for medical device and diagnostics companies experienced a dramatic slowdown in 2023. Now that the 2024 J.P. Morgan Healthcare Conference has...more
This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences...more
Meanwhile, cash-strapped biotechs have in many cases been forced to leverage relationships with big pharma to address liquidity. Cash is king in a financing environment such as we have observed over the last 18 months, and...more
Third-quarter Bay Area venture capital financings reached the highest number in the past 12 months (188), including the most Series A financings (100) since Q2 2021. However, Q3 was notably consistent with the prior quarter,...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include: Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
Substantial changes to the European life sciences and healthcare regulatory landscape are expected to reshape the sector. EU regulators have outlined a raft of reforms to modernise regulatory architecture, simplify product...more